Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2014
Locations: Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus, Nashville, Tennessee +1 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
Completed
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2014
Locations: Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee +6 locations
Conditions: Multiple Myeloma
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
08/23/2013
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Leukemia
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
08/21/2013
Locations: Vanderbilt Cancer Center, Nashville, Tennessee
Conditions: Leukemia
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
Completed
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2013
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Completed
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2013
Locations: Not set, Nashville, Tennessee
Conditions: Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms